All Posts By

admin

Closed
June 19, 2019

ELI LILLY I4V-MC-JADX

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib…
Read More
Closed
June 19, 2019

ELI LILLY I4V-MC-JADZ

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib…
Read More
Closed
June 19, 2019

ELI LILLY I4V-MC-JADV

“A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of…
Read More
Closed
June 19, 2019

ELI LILLY H9B-MC-BCDX

“A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous…
Read More
Closed
June 19, 2019

ELI LILLY ( H9B-MC-BCEI)

“Pharmacokinetic Evaluations of   Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto-Injector in Patients with…
Read More
Closed
June 19, 2019

DAIICHISANKYO PHARMA DEVELOPMENT (DS5565-A-E312)

AN OPEN-LABEL EXTENSION STUDY OF DS-5565 FOR 52 WEEKS IN PAIN ASSOCIATED WITH FIBROMYALGIA
Read More
Closed
June 19, 2019

STARPHARMA (SLP7013-017)

“A phase 3, double-blind, multicentre, randomised, placebo-controlled study to determine the efficacy and safety of…
Read More
Closed
June 19, 2019

JANSEN RESEARCH & DEVELOPMENT (CNTO136ARA3003)

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6…
Read More
Closed
June 19, 2019

DAIICHISANKYO PHARMA DEVELOPMENT (DS5565-A-E312)

AN OPEN-LABEL EXTENSION STUDY OF DS-5565 FOR 52 WEEKS IN PAIN ASSOCIATED WITH FIBROMYALGIA
Read More
Closed
June 19, 2019

STARPHARMA (SLP7013-017)

“A phase 3, double-blind, multicentre, randomised, placebo-controlled study to determine the efficacy and safety of…
Read More